Top 10 Later Stage Lead Investors: Biotechnology, Pharma & Life Sciences
| Rank | Investor Name |
|---|---|
| 1 | RA Capital Management |
| 2 | ARCH Venture Partners |
| 3 | Ally Bridge Group |
| 4 | Forbion Capital Partners |
| 5 | GV |
| 6 | Dimension |
| 7 | Column Group |
| 8 | Illumina Ventures |
| 9 | Nextech Invest |
| 10 | Gilde Healthcare Partners |
Platform science and pharma partnership appetite drive the category, with specialist funds leading most rounds. These firms are ranked by rounds led rather than participation, so this is the short list of investors actually pricing later stage deals in the category.
The CapitalDart directory identifies the right person to contact at each of these firms, with their individual investment criteria.
Rankings reflect investment activity from January 2025 through July 2026 in US and Canada companies, based on transactions matched to the CapitalDart directory. Seed and Early Stage rank by participation, Later Stage by rounds led, Private Equity by control and buyout activity. Updated periodically.